Lactobacillus helveticus R0052 alleviates liver injury by modulating gut microbiome and metabolome in D-galactosamine-treated rats.
Animals
Biomarkers
/ blood
Chemical and Drug Induced Liver Injury
/ pathology
Cytokines
/ blood
Feces
/ chemistry
Galactosamine
/ administration & dosage
Gastrointestinal Microbiome
/ drug effects
Intestines
/ drug effects
Lactobacillus helveticus
/ physiology
Liver
/ drug effects
Male
Metabolome
/ drug effects
Probiotics
/ administration & dosage
Rats
Rats, Sprague-Dawley
Acute liver injury
Gut microbiome
Lactobacillus helveticus R0052
Metabolome
Journal
Applied microbiology and biotechnology
ISSN: 1432-0614
Titre abrégé: Appl Microbiol Biotechnol
Pays: Germany
ID NLM: 8406612
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
31
07
2019
accepted:
20
10
2019
revised:
14
10
2019
pubmed:
13
11
2019
medline:
26
3
2020
entrez:
13
11
2019
Statut:
ppublish
Résumé
The liver is an important digestive gland, and acute liver failure results in high mortality. Probiotics are considered potential adjuvant therapies for liver disease. This study aimed to investigate the beneficial effects of Lactobacillus helveticus R0052 on acute liver injury and the underlying mechanisms. Sprague-Dawley rats were gavaged with L. helveticus R0052 suspensions (3 × 10
Identifiants
pubmed: 31713675
doi: 10.1007/s00253-019-10211-8
pii: 10.1007/s00253-019-10211-8
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Galactosamine
7535-00-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9673-9686Subventions
Organisme : National Natural Science Foundation of China
ID : 81790631
Organisme : National Natural Science Foundation of China
ID : 81570512
Organisme : National Key Research and Development Program of China
ID : 2018YFC2000500
Organisme : Natural Science Foundation of Zhejiang Province
ID : LQ19H030007